| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Presentation > The Seven Deadly Sins of Presentations |
|
Main Subject - The Seven Deadly Sins of Presentations
Every day, so many tens of thousands of innocent clients and employees are bored to tears by presentations that it ought to be considered a crime against humanity. According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product Are your presentations guilty of the following sins?
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in esentation. The person at the back of the crowd should easily be able to read your slides. If he or she can't, they're going to tune out. Pick a clearly readable f lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. nt that's large enough for the potential decision maker at the back of the room to read. And make sure to keep your slide backgrounds simple and clean. here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe trong>Information Overload. Presentations are supposed to support what you're saying, not tell the whole story. Otherwise, why should people listen to you d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro Use the outline of your presentation to pick and choose the main points on the screen. If you are going over a complex document, give your audience a handout to w ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ich they can refer. easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ith an image, video, chart or other illustration that is relevant and that will crystallize your main point. nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically onger presentations, take the time to put information into context. As you complete each section, flash back to the bigger picture for a moment so the audience kno and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ s how all the information fits together. This will also keep your presentation on track because if you can't fit a section into the bigger picture, it doesn't belo ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi g there. ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a of what it will do for your customer's lives. Internal presentations, be they about sales activities or manufacturing output, should also take their audience's con dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod erns into consideration. In presenting to your boss, keep the goals he's set for you and the bigger picture in mind. In presenting to staffers, reinforce the posi cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ive reasons why they should be paying attention. tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen nding, will make it hard for people to recall who presented what, especially if you're competing for attention. Make sure the design, layout, colours and font used t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel in your presentation could only have come from your company. ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust e Search, scan a Dilbert cartoon or use a track from your favourite music CD to spice up your presentation, but guess what? It's illegal. Even if you're only putti y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products g together an internal presentation: if you didn't commission the material you wish to use or get it from a royalty free source that allows business use - it's aga . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de nst the law to include it. You might not get a knock on your door from Sony music or Scott Adams (the guy that writes Dilbert), but if your boss or client is sens elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip tive about protecting intellectual property and is reasonably savvy, you could (at best) end up embarrassing yourself and at worst lose a major account.
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Interviewing Principles and Practices How to Avoid Making a Bad Hiring Decision Marketing for Local Artists; Poetry, Art, Sculpture, Photography or Paintings
|